BioPharmSignal logoBioPharmSignal

Biotech News

Carisma Therapeutics Provides Corporate Updates

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.Company update

Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA , March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a

Related news

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AUTLAutolus Therapeutics plc2026-08-11 11:00 EST

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

ELVNEnliven Therapeutics2026-10-06 20:05 EST

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.

Recent company news

CARMCarisma Therapeutics, Inc.2025-12-05 16:16 EST

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARMCarisma Therapeutics, Inc.2025-03-31 20:30 EST

Carisma Therapeutics Provides Corporate Updates

CARMCarisma Therapeutics, Inc.2025-02-19 12:30 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2025-02-05 12:30 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2024-12-09 13:30 EST

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States